A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

Description

The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research involvement for people with CF who do not take CFTR modulators, engage them in research, and give them an opportunity to learn about what is involved in participating in a CF research study.

Conditions

Cystic Fibrosis

Study Overview

Study Details

Study overview

The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research involvement for people with CF who do not take CFTR modulators, engage them in research, and give them an opportunity to learn about what is involved in participating in a CF research study.

A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

Condition
Cystic Fibrosis
Intervention / Treatment

-

Contacts and Locations

Birmingham

The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233

Phoenix

Phoenix Children's Hospital, Phoenix, Arizona, United States, 85016

Tucson

Tucson Cystic Fibrosis Center, Tucson, Arizona, United States, 85724

Little Rock

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States, 72205

La Jolla

University of California San Diego, La Jolla, California, United States, 92093

Los Angeles

Childrens Hospital Los Angeles, Los Angeles, California, United States, 90027

Palo Alto

Stanford University Medical Center, Palo Alto, California, United States, 94304

San Francisco

University of California, San Francisco - Adult Center, San Francisco, California, United States, 94143

San Francisco

University of California, San Francisco - Peds Center, San Francisco, California, United States, 94158

Aurora

Children's Hospital Colorado, Aurora, Colorado, United States, 80045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    12 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Nicole Hamblett,

    Deepika Polineni, MD, MPH, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

    Nicole Mayer-Hamblett, PhD, PRINCIPAL_INVESTIGATOR, Seattle Children's Hospital

    Henna Budhwani, PhD, MPH, PRINCIPAL_INVESTIGATOR, Florida State University

    Scott Donaldson, MD, PRINCIPAL_INVESTIGATOR, University of North Carolina, Chapel Hill

    Felix Ratjen, MD, PRINCIPAL_INVESTIGATOR, University of Toronto

    Study Record Dates

    2029-08-14